Cite
MLA Citation
Ariel Hammerman et al.. “Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.” Postgraduate medicine, vol. 134, no. 7, 2022, pp. 654–658. http://access.bl.uk/ark:/81055/vdc_100167015679.0x00005d